Welcome to our dedicated page for XORTX Therapeutics news (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on XORTX Therapeutics stock.
XORTX Therapeutics Inc. (NASDAQ: XRTX) is a bio-pharmaceutical company dedicated to developing and commercializing innovative therapies aimed at treating progressive kidney diseases worldwide. Headquartered in Calgary, Canada, XORTX focuses on addressing serious health conditions related to aberrant purine and uric acid metabolism, including diabetic nephropathy, polycystic kidney disease (PKD), and complications arising from diabetes and cardiovascular diseases.
The company has two lead programs targeting progressive kidney disease due to diabetes and PKD. Additionally, XORTX is actively involved in the development of uric acid-lowering agents to treat conditions like hypertension, insulin resistance, metabolic syndrome, and diabetes. Their pipeline includes xanthine oxidase inhibitors that show potential in managing diabetic nephropathy.
One of XORTX's strategic milestones is its alliance with Teijin Pharma Limited for the development of TMX-049, a promising xanthine oxidoreductase inhibitor. Another significant partnership is with the Icahn School of Medicine, focusing on studying acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.
XORTX Therapeutics Inc. is at the clinical-stage of biotechnology, aiming to identify, develop, and potentially commercialize therapies that can slow or reverse the progression of chronic kidney diseases. Their focus includes addressing the immediate needs of individuals facing acute kidney injury (AKI) due to respiratory virus infections and exploring other opportunities where their intellectual property can mitigate various health issues.
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) has announced the filing and mailing of meeting documents for its upcoming Annual and Special Meeting of Shareholders. The management information circular is now available on the company's website, SEDAR+, and the SEC's website. The meeting is scheduled for September 12, 2024, at 10:00 am (Calgary Time) at the company's offices.
Shareholders are encouraged to review the circular and vote their shares by September 10, 2024. The Board of Directors recommends voting FOR ALL proposed items. For assistance with voting, shareholders can contact Laurel Hill Advisory Group. The company also clarified a misreported statement regarding Patrick Treanor's board attendance in 2023.
XORTX Therapeutics Inc. (NASDAQ: XRTX) announced the acceptance of an abstract for presentation at the American Society of Nephrology's Kidney Week 2024. The abstract, titled 'Xanthine oxidase in rats, mice and humans with polycystic kidney disease', focuses on the role of xanthine oxidase (XO) in polycystic kidney disease (PKD). The study, conducted at the University of Colorado and sponsored by XORTX, aimed to understand serum xanthine oxidase activity (XOa) in PKD and its relation to total kidney volume and glomerular filtration rate (GFR) decline.
The research investigated XO activity in PCK1 rats, PKD1RC/RC mice, and 34 patients from the HALT-PKD Clinical study. Results provide insights into how aberrant purine metabolism in PKD tissue may contribute to circulating uric acid levels, kidney expansion rate, and GFR decline. This study builds on previous findings suggesting XO overexpression in PKD kidney tissue. XORTX plans to provide a detailed update on the study results in early November.
XORTX Therapeutics, a late-stage clinical pharmaceutical company focused on treating progressive kidney disease, announces its participation in the BIO International Convention 2024 from June 3-6 at the San Diego Convention Center. CEO Dr. Allen Davidoff will present an overview of the company's progress and future plans on June 4 at 3:30 pm in Theater 1. The event aims to foster outreach to pharmaceutical partners and industry contacts, with over 25 meetings scheduled. One-on-one meetings with Dr. Davidoff can be arranged through the BIO International 2024 meeting platform.
XORTX Therapeutics announced the repricing of warrants issued in October 2021, receiving approval from the TSX Venture Exchange to amend the terms. The repricing affects 101,111 warrants post a 9:1 consolidation, lowering the exercise price from USD $42.93 to USD $5.00. If the company's stock price exceeds USD $6.50 for ten consecutive trading days, warrant holders must exercise their options within 30 days or face expiration.
XORTX Therapeutics Inc. announces the amendment of 1,024,099 outstanding common share purchase warrants by changing the exercise price to USD $5.00 per share. The TSX Venture Exchange approved the amendments related to Private Placements from 2021 to 2022. Additionally, a new Warrant Acceleration Provision was introduced.
FAQ
What is the current stock price of XORTX Therapeutics (XRTX)?
What is the market cap of XORTX Therapeutics (XRTX)?
What is XORTX Therapeutics Inc.?
What are the main diseases XORTX targets?
Where is XORTX Therapeutics headquartered?
What is TMX-049?
Who are XORTX's strategic partners?
What stage is XORTX Therapeutics in?
What health issues does XORTX aim to address?
What is the focus of XORTX's pipeline?
What are xanthine oxidase inhibitors?